eprintid: 10203702 rev_number: 10 eprint_status: archive userid: 699 dir: disk0/10/20/37/02 datestamp: 2025-01-21 09:57:51 lastmod: 2025-05-29 06:10:07 status_changed: 2025-01-21 09:57:51 type: article metadata_visibility: show sword_depositor: 699 creators_name: Allameen, NA creators_name: Ramos-Lisbona, AI creators_name: Wedderburn, LR creators_name: Lundberg, IE creators_name: Isenberg, DA title: An update on autoantibodies in the idiopathic inflammatory myopathies ispublished: pub divisions: UCL divisions: B02 divisions: C10 divisions: D17 divisions: D13 divisions: G24 keywords: Science & Technology, Life Sciences & Biomedicine, Rheumatology, INTERSTITIAL LUNG-DISEASE, MYOSITIS-SPECIFIC AUTOANTIBODIES, NEUTROPHIL EXTRACELLULAR TRAPS, SIGNAL RECOGNITION PARTICLE, CYTOSOLIC 5'-NUCLEOTIDASE 1A, CONNECTIVE-TISSUE DISEASE, TRANSFER-RNA-SYNTHETASE, GENE 5, CLINICAL-SIGNIFICANCE, SYSTEMIC-SCLEROSIS note: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. abstract: Myositis-specific autoantibodies (MSAs) have become pivotal biomarkers for idiopathic inflammatory myopathies and have revolutionized understanding of the heterogeneous disease spectrum that affects both adults and children. The discovery and characterization of MSAs have substantially enhanced patient stratification based on clinical phenotype, thereby facilitating more precise diagnosis and ultimately improving management strategies. Advances in immunoassay technologies in the past 20 years have further propelled the field forward, enabling the detection of a growing repertoire of autoantibodies with high specificity and sensitivity; however, evolving research over the past decade has revealed that even within antibody-defined subsets, considerable clinical diversity exists, suggesting a broader spectrum of disease manifestations than previously acknowledged. Challenges persist, particularly among patients who are seronegative, where the failure to identify certain rare MSAs stems from the use of diverse detection methodologies and inadequate consensus-guided standardization and validation protocols. Bridging these diagnostic gaps is crucial for optimizing patient care and refining prognostic stratification in idiopathic inflammatory myopathies. date: 2025-01 date_type: published publisher: NATURE PORTFOLIO official_url: https://doi.org/10.1038/s41584-024-01188-4 oa_status: green full_text_type: other language: eng primo: open primo_central: open_green verified: verified_manual elements_id: 2339940 doi: 10.1038/s41584-024-01188-4 medium: Print-Electronic pii: 10.1038/s41584-024-01188-4 lyricists_name: Isenberg, David lyricists_name: Wedderburn, Lucy lyricists_id: DAISE40 lyricists_id: WLUCY30 actors_name: Wedderburn, Lucy actors_id: WLUCY30 actors_role: owner funding_acknowledgements: [National Institute for Health Research (NIHR)]; [NIHR-Biomedical Research Centre at Great Ormond Street Hospital]; [NIHR Senior Investigator award] full_text_status: public publication: Nature Reviews Rheumatology volume: 21 number: 1 pagerange: 46-62 pages: 17 event_location: United States issn: 1759-4790 citation: Allameen, NA; Ramos-Lisbona, AI; Wedderburn, LR; Lundberg, IE; Isenberg, DA; (2025) An update on autoantibodies in the idiopathic inflammatory myopathies. Nature Reviews Rheumatology , 21 (1) pp. 46-62. 10.1038/s41584-024-01188-4 <https://doi.org/10.1038/s41584-024-01188-4>. Green open access document_url: https://discovery.ucl.ac.uk/id/eprint/10203702/1/Wedderburn_AllameenNRRClean20012025.pdf